FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma By Ogkologos - August 14, 2025 490 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR What Is Peripheral Neuropathy and How Can It Be Prevented or... July 14, 2020 Emergency presentations: what are they, and what do they mean for... April 7, 2022 FDA Approves Alpelisib for PIK3CA-Related Overgrowth Spectrum April 13, 2022 At 27, She Was Told She Was Too Young For Breast... February 6, 2020 Load more HOT NEWS Cure Probability Models for Evaluation of Patients with a Previous Cancer... 7 Tips For Keeping The Entire Family Healthy During Flu Season ESMO Sarcoma and Rare Cancers Congress 2024 FDA Approves Pafolacianine for Identifying Malignant Ovarian Cancer Lesions
